October 30, 2018 08:02 AM EDTUpdated 08:17 AM
Financing
China

Terns scores $80M in Se­ries B fi­nanc­ing led by Vi­vo, Or­biMed

ENDPOINTS

Transpa­cif­ic biotech up­start Terns Phar­ma­ceu­ti­cals, which is fo­cused on de­vel­op­ing treat­ments for NASH and can­cer, has closed $80 mil­lion in Se­ries B fi­nanc­ing as it …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times